Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Citi
McKesson
Fuji
Chubb
UBS
Cerilliant
Merck

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE SUCCINATE

« Back to Dashboard

Clinical Trials for Desvenlafaxine Succinate

Trial ID Title Status Sponsor Phase Summary
NCT00256685 Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00283842 Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00369343 Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal.
NCT00369434 Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.
NCT00384033 Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder Completed Pfizer Phase 3 The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
NCT00397176 Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Desvenlafaxine Succinate

Condition Name

Condition Name for Desvenlafaxine Succinate
Intervention Trials
Major Depressive Disorder 17
Depressive Disorder, Major 5
Vasomotor Symptoms 4
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Desvenlafaxine Succinate
Intervention Trials
Depressive Disorder 25
Depression 25
Depressive Disorder, Major 24
Disease 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Desvenlafaxine Succinate

Trials by Country

Trials by Country for Desvenlafaxine Succinate
Location Trials
United States 410
Canada 22
Japan 21
Mexico 6
South Africa 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Desvenlafaxine Succinate
Location Trials
Florida 22
Ohio 19
California 18
Texas 17
Georgia 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Desvenlafaxine Succinate

Clinical Trial Phase

Clinical Trial Phase for Desvenlafaxine Succinate
Clinical Trial Phase Trials
Phase 4 9
Phase 3 21
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Desvenlafaxine Succinate
Clinical Trial Phase Trials
Completed 32
Terminated 3
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Desvenlafaxine Succinate

Sponsor Name

Sponsor Name for Desvenlafaxine Succinate
Sponsor Trials
Pfizer 22
Wyeth is now a wholly owned subsidiary of Pfizer 16
St. Joseph's Healthcare Hamilton 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Desvenlafaxine Succinate
Sponsor Trials
Industry 38
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fish and Richardson
US Department of Justice
Julphar
Cipla
Chinese Patent Office
Chubb
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.